Chongqing Precision Biotech Co., Ltd
Clinical trials sponsored by Chongqing Precision Biotech Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection shows promise for tough lymphoma in early trial Results expected Dec 2026 (estimated)
- Engineered immune cells take aim at a shared marker in two blood cancers Results expected Jun 2027 (estimated)
-
New CAR-T therapy targets Hard-to-Treat cancers
Disease control PausedThis early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control CancelledThis study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC